Financial Post
🏢 Postmedia
📍 ON
Aug 12, 2026
· 1 min read
AI Analyzed
○ Unverifiable
View full audit trail →
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.021
4,836 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Study met primary and all key secondary efficacy endpoints Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.4 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.81) DT120 ODT was generally well tolerated, with a safety profile consistent with prior clinical experience […]
Read full article at Financial Post ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
pending
Aug 12, 2026